Landos Biopharma, Inc. (NASDAQ:LABP) Short Interest Up 7.8% in August

Landos Biopharma, Inc. (NASDAQ:LABPGet Rating) saw a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 129,700 shares, an increase of 7.8% from the August 15th total of 120,300 shares. Approximately 0.5% of the company’s shares are sold short. Based on an average daily volume of 109,400 shares, the short-interest ratio is currently 1.2 days.

Institutional Investors Weigh In On Landos Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LABP. Acadian Asset Management LLC purchased a new stake in Landos Biopharma during the 4th quarter worth $39,000. Walleye Capital LLC acquired a new position in Landos Biopharma during the 4th quarter worth $505,000. BlackRock Inc. grew its holdings in Landos Biopharma by 10.6% during the 1st quarter. BlackRock Inc. now owns 520,308 shares of the company’s stock worth $767,000 after acquiring an additional 49,880 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Landos Biopharma by 99.0% during the 1st quarter. Renaissance Technologies LLC now owns 340,500 shares of the company’s stock worth $502,000 after acquiring an additional 169,400 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in Landos Biopharma by 80.4% during the 1st quarter. Bank of America Corp DE now owns 56,321 shares of the company’s stock worth $83,000 after acquiring an additional 25,096 shares in the last quarter. Hedge funds and other institutional investors own 63.50% of the company’s stock.

Landos Biopharma Price Performance

Landos Biopharma stock opened at $0.88 on Tuesday. Landos Biopharma has a 12-month low of $0.55 and a 12-month high of $16.17. The company has a market capitalization of $35.29 million, a price-to-earnings ratio of -0.59 and a beta of 0.81. The firm’s fifty day moving average price is $0.91 and its 200 day moving average price is $1.01.

Analyst Ratings Changes

LABP has been the topic of a number of recent analyst reports. Raymond James downgraded shares of Landos Biopharma from an “outperform” rating to a “market perform” rating in a research note on Friday, August 12th. SVB Leerink cut their target price on shares of Landos Biopharma from $16.00 to $3.00 and set a “market perform” rating on the stock in a research note on Friday, August 12th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, Landos Biopharma has a consensus rating of “Hold” and an average target price of $22.92.

About Landos Biopharma

(Get Rating)

Landos Biopharma, Inc, a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA).

Read More

Receive News & Ratings for Landos Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Landos Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.